Business
Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis
Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthriti...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n -  Company remains on track for Phase 2 data readout in Q2 2023 -\n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Dec. 7, 2022\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has completed enrollment, randomization and dosing of the last patient, in its Phase 2 trial that is evaluating the efficacy and safety of EP-104 for the treatment of osteoarthritis (\"OA\") of the knee.\n \n \n \"Eupraxia has successfully achieved another important clinical milestone in our ongoing Phase 2 trial, removing patient accrual risk by dosing our last patient,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"The entire team has worked tirelessly to fully enroll the study during a time when many biotech companies are facing challenges enrolling trials. With this important step behind us, we remain confident in our ability to report top-line trial results in the second quarter of 2023.\"\n \n \n The trial's primary endpoint is the difference in change from baseline between EP-104 and placebo in the\n \n Western Ontario\n \n and McMaster Universities Osteoarthritis Index (\"WOMAC\") pain subscale at 12 weeks, with a key secondary endpoint at 24 weeks. Additional key secondary endpoints include the difference in change from baseline between EP-104 and placebo in the WOMAC function subscale.\n \n \n A magnetic resonance imaging (\"MRI\") sub-study was also added to the trial's protocol late in the enrollment period to further characterize the safety profile of EP-104 and potentially strengthen EP-104's differentiation as a treatment for OA.\n \n \n Eupraxia also continues to advance its ongoing Phase\n \n 1b\n \n /2a trial evaluating EP-104's safety and efficacy as a treatment...